Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib
in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second
line chemotherapy.